ГоловнаArchive of numbers2013Volume 21, issue 3 (76)"Zeldox — antipsychotic for the mind and body" — Myth or Reality? (Tested by KRPNMU)
Title of the article "Zeldox — antipsychotic for the mind and body" — Myth or Reality? (Tested by KRPNMU)
Authors Zilberblat Gennadii
Yershova O.
Тimеn М. Е.
Year 2013 Issue Volume 21, issue 3 (76) Pages 136-143
Type of article Scientific article Index UDK 616.893:616-08:614.2. Index BBK -
Abstract The paper presents the results of the drug zeldox with diff erent group of mental illnesses, diff erent axial syndromes. Effi ciency of zeldox is shown during exacerbation of the illness and stabilization of the mental condition; the most common side eff ects of the drug and the evaluation of the drug by patients are noted. Zeldox can be actively used as a broad-spectrum antipsychotic in psychiatric practice.
Key words zeldox, schizophrenia, cognitive disorders, side reactions, compliance therapy
Access to full text version of the article pdf download
Bibliography 1.Ушкалова Е. А. Зипрасидон — высокоэффективный ати- пичный нейролептик с улучшенным профилем безопасности / Е. А. Ушкалова, А. В. Ушкалова // Фарматека. — 2005. — № 17. — С. 10—19.
2. Меллер Х. И. Об атипичном антипсихотике зипрасидоне / Х. И. Меллер // Обозрение психиатрии и медицинской психологии. — 2006. — № 1. — С. 46—48.
3. От клинико-научных исследований к клинической практи- ке : обзор данных 4-летнего применения зипрасидона (расширенный реферат) / [C. B. Nemeroff, J. W. Newcomer, J. A. Lieberman, et al.]. Часть I, II // Consilium medicum Психиатрия и психофар- макология. — 2006. — Т. 08. — № 5, 6.
4. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential / Tandon R., Harrihan E., Zorn S. H. // J. Serotonin Res. — 1997; 4: 159—77.
5. Ziprasidone: a novel atipsychotic agent with a unique human receptor binding profile / [Schmidt A. W., Lebel L. A., Howard H. R., Zorn S. H.] // Eur J. Pharmacol. — 2001; 425: 197—201.
6. 5-HT1A-receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex / [Rollema H., Lu Y., Schmidt A. W., Sprouse J. S., Zorn S. H.] // Biol. Psychiatry. — 2000; 48: 229—37.
7. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbatieon of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial / [Daniel D. G., Zimbroff D. L., Potkin D. G., Reeves K. R., Harrigan E. P., Lakshminarayanan M., and the Ziprasidone Study Group] // Neuropsychophsrmacolohy. — 1999; 20: 491—505.
8. Ziprasidone vs olanzapine in schizophrenia / [Simpson G., Weiden P. J., Pigott T., et al.]. Presented at: American Psychiatric Association Annual Meeting, May 2001; New Orleans, La.
9. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerabillity of ziprasodone and olanzapine in acutely ill in patients with schizophrenia or schizoaffective disorder / [Simpson G. M., Glick I. D., Weiden P. J. et al.] // Am J. Psychiatry. — 2004; 161: 1837—1847.
10. Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative / [Thomas H. McGlashan, Tandy J. Miller, Robert B. Zipursky, et al.] // Presenter at: 156th Annual Meeting of the American Psychiatric Association; May 17—22, 2003; San Francisco, Calif. — № 39B. — Р. 96.
11. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial / [Addington D. E., Pantelis C., Dineen M. et al.] // J Clin Psychiatry. — 2004 Dec; 65 (12): 1624—33.
12. Ziprasidone in schizophrenia / [Addington D., Pantelis C., Dineen M., et al.]: 52-week continuation study. In: Essentials of Clinical Psychopharmacology, Third Edition. — 2005. — P. 350.
13. Murray S. et al. Optimal dosing of oral ziprasidone: analysis of clinical trial data [abstract] // Presented at the 156th Annual Meeting of the American Psychiatric Association; May 17—22, 2003; San Francisco, Calif.